On May 8, 2026, the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control (“OBNDD”) issued a directive that may be the first of its kind in the post-Schedule III landscape: a mandate that state-licensed medical marijuana manufacturers and distributors obtain federal DEA registration or risk losing their state OBNDD registration. The letter, signed by OBNDD Director Donnie Anderson, gives operators until January 1, 2027 before administrative enforcement begins. But the message is clear: in Oklahoma, federal registration is no longer a strategic choice. It is a condition of continued state operation for two specific license categories.
The OBNDD letter raises a question every state-licensed medical marijuana operator in the country should now be asking: Is DEA registration mandatory?
What Just Happened in Oklahoma
The April 28, 2026 publication of the DOJ’s Final Order in the Federal Register set off a 60-day expedited registration window for state-licensed medical marijuana operators under 21 C.F.R. § 1301.13(k). Operators who file within that window get priority processing and a safe harbor that allows them to continue operating under their state license while DEA review is pending.
Up to May 8, the conversation around this window had been framed in opt-in language. In fact, the Oklahoma Medical Marijuana Authority’s (“OMMA”) April 28 release explicitly state, in part, that “Dispensaries choosing not to participate may continue to operate in accordance with the existing regulatory framework in Oklahoma and may still be eligible for potential tax breaks.“
The OBNDD letter changes that frame for two specific operator categories in Oklahoma.
Citing 63 O.S. § 2-101 et seq. and Title 475 of the Oklahoma Administrative Code, the letter takes the position that any OBNDD-registered manufacturer or distributor of medical marijuana products must comply with federal law to maintain their state registration and that compliance with federal law now requires DEA registration, given Schedule III’s regulatory framework. Failure to obtain DEA registration, the letter warns, “could result in OBNDD administrative sanctions up to and including the potential revocation of an registrant’s OBNDD registration(s).”
Is DEA Registration Actually Mandatory? Both Sides
The threshold question every operator outside Oklahoma (and perhaps dispensaries within Oklahoma) is asking is whether DEA registration is, as a matter of federal law, mandatory at all. Let’s evaluate both sides.
The case that registration is mandatory rests on the architecture of the CSA itself. Schedule III substances may only be lawfully manufactured, distributed, or dispensed by entities that hold valid DEA registrations under 21 U.S.C. § 822. Once a substance is in Schedule III, the absence of registration becomes a CSA violation. Under this reading, the moment the Final Order took effect, every state-licensed medical marijuana operator handling now-Schedule-III products without a DEA registration was technically out of federal compliance. The 60-day expedited window and the safe harbor for pending applications are not optional benefits; they are transitional accommodations recognizing that the industry could not realistically register overnight. Under this view, OBNDD’s letter is not creating a new federal obligation. It acknowledges an existing one and warns operators that state administrative consequences will follow if they ignore it.
The case that registration is optional rests on the Final Order’s own framing and on how DOJ has chosen to enforce it. The Order describes federal registration as a “pathway” and an “expedited registration framework.” It does not, by its terms, declare unregistered state-licensed operators to be in violation. DEA’s published instructions are couched in opt-in language. OMMA’s April 28 release explicitly told dispensaries they could choose not to participate. The Department of Justice has not announced any enforcement priority targeting unregistered state-licensed medical marijuana operators, and past enforcement traditions (or lack thereof) may suggest no such priority is coming. Section 280E tax relief flows to state-licensed operators regardless of whether they register. Under this reading, registration is a federally encouraged pathway with significant benefits, but operators who do not register are in roughly the same federal posture they occupied on April 27, 2026: operating in violation of an unenforced federal prohibition, with state license cover, while DOJ looks the other way.
Could We May See a Divergence Between Medical-Only and Dual-Market States?
The regulatory landscape may begin to fracture along an important and often-overlooked dimension: whether a state operates a medical-only market or a dual medical-and-recreational market.
The Final Order rescheduled state-licensed medical marijuana to Schedule III. It did not reschedule recreational marijuana, which remains Schedule I. In a medical-only state like Oklahoma, every state-licensed cannabis product handled by a manufacturer or distributor is now a Schedule III substance. DEA registration is conceptually clean. It maps onto the operator’s actual operations.
In a dual-market state: Maine, Massachusetts, New York, California, Colorado, and most of the larger cannabis markets, the regulatory picture is dramatically different. State-licensed operators in those jurisdictions routinely handle both Schedule III medical product and Schedule I recreational product, often within the same vertically integrated operation. A single licensed manufacturer may be making medical product on one production line and adult-use product on another. A single licensed distributor may be moving both kinds of inventory. The DEA registration framework was not designed for this. It was designed for entities handling controlled substances of a single schedule under a unified federal authorization.
This creates a structural problem that medical-only states do not face. Mandating DEA registration for a manufacturer in a dual-market state would mean federally registering a handler of Schedule III substances who is, at the very same facility, openly handling Schedule I substances. That is not just an awkward regulatory posture; it is an affirmative invitation for federal scrutiny over the recreational side of the same operation. It would put state regulators in the position of having engineered the federal exposure of their own licensees.
Maine’s Early Signal: Anticipate No Changes
Maine has already provided what may be the clearest dual-market state response on record. Following President Trump’s December 2025 executive order directing the Attorney General to complete rescheduling, the Maine Office of Cannabis Policy issued a statement that anticipated essentially no programmatic changes flowing from the move. The statement is worth reading carefully.
OCP’s statement made several points. First, it acknowledged that the rescheduling did not change the underlying federal-law incompatibility of state-regulated cannabis programs: programs that were inconsistent with federal law as Schedule I would remain inconsistent with federal law as Schedule III. Second, it grounded its no-change prediction in DOJ’s non-enforcement posture across “the past four presidential administrations” and stated that OCP “fully expects there to be no change to that posture.” Third, it framed the meaningful federal-side consequences of rescheduling as primarily tax-related (the 280E delinking) and research-related (lower bureaucratic hurdles for scientific study). Fourth, and most relevant for present purposes, it did not mention DEA registration at all.
That last point matters. Maine OCP’s statement was issued before the Final Order’s specific terms were public, so the specifics of the 60-day expedited registration window and 21 C.F.R. § 1301.13(k) were not before the agency at the time. But OCP’s chosen framing already signaled the dual-market posture: rescheduling was characterized as a tax and research event, not a registration event.
Compare that to OBNDD’s May 8 letter, and the divergence is stark. Oklahoma’s state CSA agency reads the post-Schedule III landscape as one in which DEA registration is not just available but mandatory for manufacturers and distributors under existing state law. Maine’s cannabis regulator reads the same landscape as one in which the established non-enforcement posture continues and programmatic changes are not anticipated. Both readings are defensible on their own terms. The difference between them is structural: a medical-only state with a separate CSA agency is positioned to require federal registration; a dual-market state with a single cannabis regulator is positioned to absorb the federal change without disrupting its state framework.
Two Further Variables
Two additional factors compound the divergence. The first is agency structure. Oklahoma’s regulatory split between OMMA (the cannabis program regulator) and OBNDD (the state CSA enforcement agency) is unusual. Most cannabis states have a single cannabis-program regulator without a separate, parallel CSA-enforcement agency that has its own registration scheme. That structural split is what gave OBNDD the legal hook to act independently of OMMA. States without that split would have to push registration mandates through their cannabis regulators, which face a different, more political set of considerations. Maine’s OCP, for example, regulates both the medical and adult-use programs and has no separate state-level CSA registration regime to leverage. Even if OCP wanted to mandate DEA registration, the statutory pathway would be much harder to construct.
The second is timing. Operators who file within the 60-day window get a defined safe harbor. Operators who do not are in the standard queue. State regulators’ enforcement choices over the next six to nine months will be influenced by how many of their licensees actually filed within the window, which they will not know until the window closes on or about June 27, 2026.
Florida, Mississippi, Pennsylvania, and other medical-only states may be likely candidates to issue OBNDD-style guidance in the coming months. Massachusetts, New York, California, Colorado, and other dual-market states may be more likely to follow Maine’s pattern: silence or guidance that characterizes federal registration as optional and emphasizes non-enforcement traditions.
Practical Implications for Operators
For Oklahoma manufacturers and distributors, the OBNDD letter is the regulatory equivalent of a deadline notice. Operators in those categories face two different timelines: the federal 60-day expedited window (closing June 27, 2026) and the OBNDD enforcement window (opening January 1, 2027). The right move for most is to file within the federal window. Doing so secures the safe harbor, locks in the federal six-month processing target, and forecloses OBNDD administrative exposure. Operators who choose not to register should document the timeline and basis for that decision carefully, particularly in light of the SAM/NDASA petition filed May 4, 2026 in the D.C. Circuit seeking review of the Final Order.
For operators outside Oklahoma, the OBNDD letter is a leading indicator, not a binding directive. It signals where state CSA agencies in medical-only jurisdictions are likely to land. It does not, on its own, change the regulatory calculus in California, Massachusetts, New York, Maine, or any other dual-market state. Those states’ regulators have not issued comparable guidance, and Maine OCP’s statement explicitly anticipates no programmatic changes. Operators in those states should evaluate federal registration on its own merits: the benefits of the federal expedited window, the 280E delinking, and the eventual implications for interstate commerce and banking. They should also continue to monitor their own state regulator’s posture, recognizing that statements may evolve as the SAM/NDASA litigation plays out and as the 60-day federal window closes.
For multistate operators, the picture is more complex. An MSO with a presence in both Oklahoma and Maine may face a registration mandate in Oklahoma, an absence of state guidance in Maine, and the operational question of how to handle a federal registration that applies to one part of the enterprise but not others. The 60-day window forces these decisions on a compressed timeline.
A Caveat
The DEA has scheduled an administrative hearing beginning in late June 2026 to consider whether all forms of marijuana (including recreational should be moved to Schedule III through formal rulemaking. The outcome is uncertain. A broader rescheduling would substantially flatten the distinction between medical-only and dual-market. A narrow ruling that leaves recreational in Schedule I would entrench the divergence and likely accelerate the OBNDD-versus-Maine pattern across more states. The SAM/NDASA petition pending before the D.C. Circuit could also reshape the underlying Final Order before the June hearing concludes. Until the June hearing concludes and any subsequent rulemaking takes effect, operators and counsel should understand that the underlying federal regime could shift.
A Federal Question That Will Keep Coming Up
The OBNDD letter is likely the first of several state-level enforcement decisions about DEA registration. As more medical-only states act, and as dual-market states either decline to act or issue more nuanced guidance, the regulatory landscape could become genuinely fragmented. Operators will need to track not just the federal Final Order and the SAM/NDASA litigation, but also state-by-state enforcement postures that may shift on a weekly cadence over the next year.
We will be tracking these developments closely on this blog. State-licensed medical marijuana operators who need federal DEA registration counsel can reach Kocot Law at (916) 572-6445 or through our free consultation form. We work with operators in any state on the federal registration piece and partner with local counsel on state-specific matters as needed.
This post is for general informational purposes only and does not constitute legal or tax advice. Visiting this website does not establish an attorney-client relationship. Past results do not guarantee future outcomes. Attorney advertising.
